Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC ... (Micromet Inc. (h Micromet Inc. is a b...)

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference

Date:10/23/2007

Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody developed utilizing the BiTE(R) technology platform to be clinically validated in Micromet's product pipeline, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono in a phase 1b clinical trial evaluating MT201 in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293, which is currently being tested in a phase 1 clinical trial, is licensed to TRACON Pharmaceuticals, Inc. and is being developed for the treatment of patients with cancer and age- related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Simple, Sensitive Isotyping of Mouse Monoclonal Antibodies
3. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
4. Mirus announces new method for making antibodies
5. Olympics of biotechnology has international flavor
6. Traffic data firm navigates international business
7. Catalyst International profit exceeds expectations
8. Lack of broadband hamstrings international videoconferencing
9. 30 days to success: Three simple steps to create your own international startup
10. TEKLYNX International announces new RFID software
11. Ruling enforces international trademark electronic filing requirements

Post Your Comments:

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC ...(Micromet Inc. (h Micromet Inc. is a b...)